Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 79

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 79
---
, develop new products, expand
direct to patient education and outreach, conduct or sponsor clinical studies and trials, grow our marketing program and provide for
working capital and other general corporate purposes. However, our use of these proceeds may differ substantially from our current plans.
If we do not invest or apply the proceeds of this offering in ways that improve our operating results, we may fail to achieve expected
financial results, which could cause our share price to decline.

New investors purchasing our securities will experience immediate and substantial dilution.

Our initial public offering
price is substantially higher than the book value per share of our Ordinary Shares. If you purchase securities in this offering, you
will incur immediate dilution of $9.74 in net tangible book value per Ordinary Shares, based on an assumed initial public offering price
of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus. In addition, the
number of shares available for issuance under our stock option plans will increase annually without further shareholder approval. Investors
will incur additional dilution upon the exercise of stock options. See “Dilution” for more information.

Risks Related to Israeli Law and Our Operations in Israel

Political, economic and military instability in the State of Israel, including as a result of the current “Iron Swords” war in Israel, where our headquarters, members of our management team and our research and development facilities are located, may adversely affect our results of operations.

Our
executive offices and research and development laboratories are located in Herzliya, Israel. In addition, the majority of our key employees,
officers and directors are residents of Israel. Accordingly, political, economic and military conditions in the Middle East may affect
our business directly. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel
and its neighboring countries and terrorist organizations active in the region, including Hamas (an Islamist militia and political group
in the Gaza Strip) and Hezbollah (an Islamist militia and political group in Lebanon).

In
particular, in October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of
attacks on civilian and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers
located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands
of deaths and injuries, and Hamas additionally kidnapped many Israeli civilians and soldiers